The retromer protein complex assists in recycling selected integral membrane proteins from endosomes to the trans Golgi network. One protein subcomplex (Vps35p, Vps26p and Vps29p) combines with a second (Vps17p and Vps5p) to form a coat involved in sorting and budding of endosomal vesicles. Yeast Vps35p (yVps35) exhibits similarity to human Vps35 (hVps35), especially in a completely conserved PRLYL motif contained within an amino-terminal domain. Companion studies indicate that an R 98 W mutation in yVps35 causes defective retromer assembly in Saccharomyces cerevisiae. Herein, we find that the expression of hVps35 in yeast confers dominant-negative vacuolar proenzyme secretion and defective secretory proprotein processing. The mutant phenotype appears to be driven by hVps35 competing with endogenous yVps35, becoming incorporated into defective retromer complexes and causing proteasomal degradation of endogenous Vps26 and Vps29. Increased expression of yVps35 displaces some hVps35 to a 100 000 3 g supernatant and suppresses the dominant-negative phenotype. Remarkably, mutation of the conserved R 107 W of hVps35 displaces some of the protein to the 100 000 3 g supernatant, slows protein turnover and restores stability of Vps26p and Vps29p and completely abrogates dominant-negative trafficking behavior. We show that hVps35 coprecipitates Vps26, whereas the R 107 W mutant does not. In pancreatic beta cells, the R 107 W mutant shifts hVps35 from peripheral endosomes to a juxtanuclear compartment, affecting both mannose phosphate receptors and insulin. These data underscore importance of the Vps35 PRLYL motif in retromer subcomplex interactions and function. It has previously been shown that upon expression of an insulin-containing fusion protein in Saccharomyces cerevisiae, molecules that fail to undergo Kex2-mediated endoproteolysis are rapidly secreted, whereas the processed insulin fraction is transported to the vacuole (1). A genetic screen identified six single gene disruptions allowing enhanced immunoreactive insulin secretion because of defective Kex2-mediated endoproteolytic processing; of these, vps35 showed the strongest phenotype (1). VPS35 encodes a subunit of retromer, a coat protein complex engaged in the retrieval of recycling membrane proteins from endosomes to the trans Golgi network (2). Protein recycling is essential for protein sorting in the vacuolar/ lysosomal biogenesis pathway as well as for lumenal protein processing in both secretory and endosomal systems (3). Moreover, retromer function is essential for the development and viability of mammalian organisms (4).
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The retromer protein complex assists in recycling selected integral membrane proteins from endosomes to the trans Golgi network. One protein subcomplex (Vps35p, Vps26p and Vps29p) combines with a second (Vps17p and Vps5p) to form a coat involved in sorting and budding of endosomal vesicles. Yeast Vps35p (yVps35) exhibits similarity to human Vps35 (hVps35), especially in a completely conserved PRLYL motif contained within an amino-terminal domain. Companion studies indicate that an R 98 W mutation in yVps35 causes defective retromer assembly in Saccharomyces cerevisiae. Herein, we find that the expression of hVps35 in yeast confers dominant-negative vacuolar proenzyme secretion and defective secretory proprotein processing. The mutant phenotype appears to be driven by hVps35 competing with endogenous yVps35, becoming incorporated into defective retromer complexes and causing proteasomal degradation of endogenous Vps26 and Vps29. Increased expression of yVps35 displaces some hVps35 to a 100 000 3 g supernatant and suppresses the dominant-negative phenotype. Remarkably, mutation of the conserved R 107 W of hVps35 displaces some of the protein to the 100 000 3 g supernatant, slows protein turnover and restores stability of Vps26p and Vps29p and completely abrogates dominant-negative trafficking behavior. We show that hVps35 coprecipitates Vps26, whereas the R 107 W mutant does not. In pancreatic beta cells, the R 107 W mutant shifts hVps35 from peripheral endosomes to a juxtanuclear compartment, affecting both mannose phosphate receptors and insulin. These data underscore importance of the Vps35 PRLYL motif in retromer subcomplex interactions and function. It has previously been shown that upon expression of an insulin-containing fusion protein in Saccharomyces cerevisiae, molecules that fail to undergo Kex2-mediated endoproteolysis are rapidly secreted, whereas the processed insulin fraction is transported to the vacuole (1) . A genetic screen identified six single gene disruptions allowing enhanced immunoreactive insulin secretion because of defective Kex2-mediated endoproteolytic processing; of these, vps35 showed the strongest phenotype (1) . VPS35 encodes a subunit of retromer, a coat protein complex engaged in the retrieval of recycling membrane proteins from endosomes to the trans Golgi network (2) . Protein recycling is essential for protein sorting in the vacuolar/ lysosomal biogenesis pathway as well as for lumenal protein processing in both secretory and endosomal systems (3) . Moreover, retromer function is essential for the development and viability of mammalian organisms (4) .
The core of the retromer protein complex involves a large protein subcomplex comprised of Vps35, Vps29 and Vps26 (5) along with a smaller subcomplex comprised of Vps17 and Vps5 (6) . With potential contributions from ancillary proteins, these two subcomplexes assemble into a multimeric membrane coat. Of the members of the retromer complex, yeast Vps35 has been shown to directly bind to the structural information encoded in the cytosolic domains of recycling integral membrane proteins (7, 8) , which could help to sequester these proteins into endosomal-derived membrane recycling intermediates (5) . Vps26 binds to Vps35 and has been implicated as a potential molecular bridge between the two protein subcomplexes (9) .
The ease of yeast genetics has facilitated advances in understanding eukaryotic protein sorting and recycling in the secretory/endosomal pathways. The function of the mammalian retromer complex is similar to that found in simpler eukaryotes (10, 11) , and its subunits exhibit structural conservation with those of yeast (12) and plants (13) . The activity of mammalian-yeast chimeras of retromer proteins (9) underscores the commonality of their function through retention of conserved domains. With respect to lysosomal biogenesis, analogous to its function in yeast, human Vps35 (hVps35) actively engages and assists in the recycling of the cation-independent mannose 6-phosphate receptor (CI-MPR) (8, 14) . In subcomplex assembly, twohybrid analyses and pull-down experiments suggest that hVps26 and hVps29 bind independently to an N-terminal and C-terminal region, respectively, of hVps35 (15, 16) .
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Regarding the N-terminal region, recent studies suggest that the PRLYL 101 motif in yeast Vps35 (yVps35) is likely to be an important site for protein interaction with Vps26, requiring the R 98 residue of yVps35 (17) .
In the present study of yeast cells, we have tried to examine the ability of hVps35 (which shares a highly conserved amino-terminal domain including 100% identity in the PRLYL 110 motif) to interact with the yeast retromer complex. We now establish this conserved amino-terminal domain as responsible for hVps35 behaving as a dominant negative in yeast cells, which is entirely dependent upon the presence of R 107 (the functional equivalent of R 98 in yVps35), and the binding activity of this residue for Vps26.
Results
The conserved amino-terminal domain of yVps35 and hVps35 Potential dominant-negative alleles of yeast VPS35 were prepared by random mutagenesis, subcloned into a lowcopy centromeric plasmid, transformants screened for increased carboxypeptidase Y (CPY) secretion and dominant-negative constructs rescued and sequenced (17) . Notable amongst these was the high percentage of mutants that possessed alteration at the R 98 residue contained within a conserved motif between yVps35 and hVps35 such that R 98 of yVps35 corresponds to residue R 107 in hVps35 ( Figure 1A ). Indeed, a single yVps35R 98 W mutant functions as a dominant negative in vacuolar protein sorting, indicating that at least one yVps35 partner protein interaction is lost by this mutation (17) .
A chimeric protein (nhcy1: N-human, C-yeast) containing the N-terminal region of hVps35 up to residue 263 fused in frame to residues 245-944 of yVps35 was prepared to examine whether this hVps35 region (including the nearly identical A 83 -G 106 region) was functional in yeast and whether subsequent introduction of the R 107 W mutation would confer a similar dominant-negative vacuolar protein sorting phenotype. Indeed, in a vps35D background, nhcy1 expression could complement partially with virtually all activity lost in the presence of the R 107 W mutation ( Figure 1B ). This was confirmed quantitatively by CPY immunoprecipitation after pulse-chase analysis ( Figure 1C) . In a wild-type strain background, dominant-negative vps behavior of nhcy1 was augmented by introduction of the R 107 W mutation ( Figure 1D ) and confirmed by quantitative CPY immunoprecipitation ( Figure 1E ). These data argue strongly that R 98 of yVps35, and the homologous R 107 of hVps35, is likely to be an important conserved residue for interaction within the yeast retromer complex.
Dominant-negative action of hVps35 in yeast cells
In addition to untagged hVps35, two versions of hVps35 were prepared that were epitope tagged on the amino or carboxyl terminus, respectively. Despite being driven by the strong TDH3 promoter, none of these versions could complement a vps35D mutant (Figure 2A ). However, HAhVps35, C-terminal myc-tagged human Vps35 (hVps35-myc) and untagged hVps35, each exhibited comparable perturbation of vacuolar protein sorting relative to wild-type yeast transformed with an empty vector ( Figure 2B ). By pulse-chase analysis, expression of either hVps35-myc or HA-hVps35 induced significant secretion of the newly synthesized P2 (post Golgi) form of CPY, accompanied by a dramatic reduction in the intracellular appearance of the mature vacuolar CPY ( Figure 2C ). For convenience, most of the further studies employed hVps35-myc. Expression of TDH3-hVps35-myc also interfered with proalpha factor processing ( Figure 3) . Thus, hVps35 exhibited dominantnegative behavior on protein trafficking within the secretory/ endosomal system. If hVps35 competes with yVps35 for one or more retromerbinding partners, then such dominant-negative behavior might be expected to be suppressed under conditions where yVps35 protein is overexpressed. As predicted, expression of VPS35 on a high-copy plasmid resulted in decreased CPY secretion from strains bearing hVps35-myc ( Figure 4A ).
Consistent with the notion that hVps35 engages in protein interaction with endogenous yeast retromer, we found that hVps35-myc was essentially, quantitatively pelleted with membranes after 1 h at 100 000 Â g ( Figure 4B ). When the expression of yVps35 was increased, a modestly increased fraction of hVps35-myc could be recovered in the supernatant, suggesting some degree of displacement of hVps35-myc by yVps35. These data strongly suggest that the dominant-negative behavior of hVps35 represents competition with yVps35 for binding with partners in the retromer endosomal membrane coat. R 107 is required for the dominant-negative activity of hVps35 in yeast cells To test the role of R 107 within the conserved PRLYL motif in the association of hVps35 with the yeast retromer, we created the hVps35R 107 W-myc mutant and examined its effect on CPY secretion and proalpha factor processing. As shown in Figure 5A , the hVps35R 107 W mutant is indeed expressed as a myc-Western blottable protein (of approximately 75 kDa) in yeast cell lysates. However, while hVps35 exhibited a clear dominant-negative vacuolar protein sorting defect, hVps35R 107 W was without effect on CPY secretion ( Figure 5B ; with comparable effects observed in pulsechase experiments, not shown). Similarly, the proalpha factor processing defect of hVps35 was abrogated by the presence of the R 107 W mutation ( Figure 5C ).
We examined the effect of the R 107 W mutation on the relative stability and sedimentation of hVps35 in yeast cells. As shown in Figure 6A , newly synthesized (metabolically labeled) hVps35-myc exhibited a slightly higher turnover than did hVps35R 107 W-myc (discussed further below). Significantly, although a high degree of sedimentation was observed after 1 h at 100 000 Â g, a modestly increased fraction of hVps35R 107 W-myc could be recovered in the supernatant compared with that seen for hVps35-myc ( Figure 6B ), indicating diminished membrane association for the R 107 W mutant. The latter results suggest that hVps35, by virtue of R 107 , participates in a defective membrane-bound yeast retromer complex.
A recent study suggests that the PRLYL 101 motif of yVps35 is engaged with yVps26 (17) . To determine if R 107 of hVps35 similarly engages yVps26, coimmunoprecipitation Figure 1 : Mutation of the conserved R 107 residue induces a dominant-negative phenotype in the context of a chimera of hVps35-yVps35. A) Within a conserved domain extending to residue 288 of yVps35, a sequence of near identity surrounds yVps35-R 98 , corresponding to hVps35-R 107 (enlarged font). The 'nhcy1' chimera was constructed to contain the N-terminal 263 residues of hVps35 linked to C-terminal residues 245-944 of yVps35. Panels B-E each employ low-copy YCp plasmids with expression driven by the TDH3 promoter. B) Wild-type (WT) (W303) and vps35D mutant strains are shown in duplicate above, while nhcy1 (in quadruplicate) exhibits partial complementation of vacuolar protein sorting in a vps35D background. The R 107 W mutant of nhcy1 exhibits no complementation. C) vps35D mutant cells transformed with empty vector (control) or plasmids encoding yVps35, nhcy1 or nhcy1-R 107 W were pulse labeled for 10 min with 35 S-amino acids and chased for 45 min before immunoprecipitation of CPY from intracellular (I) and extracellular (E) fractions. Quantification of these data is summarized beneath the panel. D) Wild-type control (W303) and vps35D mutant strains are shown above, while the nhcy1 mutant (in quadruplicate) produces a milder dominant-negative phenotype than does the nhcy1-R 107 W mutant. Not shown in panels B þ D: expression of yVps35 in vps35D cells resulted in CPY secretion comparable to controls. E) Wild-type SNY36-9A cells transformed with empty vector (control) or plasmids encoding expression of yVps35, nhcy1 or nhcy1-R 107 W were analyzed as in panel C with quantification of the data shown below. 'p2' form ¼ uncleaved Golgi-modified precursor; 'm' form ¼ mature vacuolar species. experiments were performed in strains lacking endogenous VPS35 or VPS26 but containing epitope (HA-) tagged yVps26 and myc-tagged hVps35 or hVps35R 107 W. When normalized for equal levels of yVps26 ( Figure 6C , upper panel), the immunoprecipitation of yVps26 (anti-HA) could coprecipitate a significant fraction of hVps35-myc but very little hVps35R 107 W, while the supernatant (non-immunoprecipitated) portion of hVps35R 107 W was increased (only 3.2% of the supernatant was loaded; Figure 6C , lower panel). The data strongly support that hVps35 requires R 107 in order to engage Vps26 in a stable retromer interaction.
Effect of hVps35R 107 on yeast retromer components
The increased turnover of hVps35-myc seemed consistent with the possibility that hVps35 might participate in unstable, defective yeast retromer protein complexes. To examine this more closely, strains were constructed bearing chromosomal, integrated copies of HA epitopetagged Vps26, Vps29 and Vps17. HA-Vps5 was expressed under the control of its own promoter from a centromeric (CEN) plasmid in a vps5D strain. Triplicate independent yeast colonies bearing hVps35 exhibited levels of Vps29-HA or HA-Vps26 that were lower than their wild-type counterparts bearing vector alone ( Figure 7) . Interestingly, the R 107 W mutation resulted in complete restoration of Vps29-HA and HA-Vps26 levels ( Figure 7 ). Neither the levels of HA-Vps5 nor HA-Vps17 were affected by the presence of hVps35 ( Figure 7 ). The data support that the expression and incorporation of hVps35 into defective yeast retromer induced instability of the two partner proteins in the large retromer subcomplex.
We also examined endogenous, untagged Vps26 in wildtype yeast cells expressing hVps35-myc. Western blotting clearly indicated that Vps26 protein levels were lower than in cells transformed with empty vector ( Figure 8A , upper panel). However, the decrease in Vps26 levels was less S-amino acids for 50 min as described in Materials and Methods. The media from each strain was immunoprecipitated with an antibody recognizing alpha factor-containing peptides. The positive control (Pos. control) comes from the secretion from a kex2D strain. In this SDS-PAGE system, a number of partially processed alpha factor peptides run with mature alpha factor at the dye front (arrowhead). apparent in pre1 pre2 cells that are deficient for proteasomal degradation ( Figure 8A , lower panel). Preservation of Vps26 levels by proteasome dysfunction did not rescue the vps (CPY missorting) phenotype caused by hVps35 ( Figure 8B ). The data suggest that sequentially, hVps35 first participates in formation of defective yeast retromer and thereafter, components of the dysfunctional complex are degraded at least in part by proteasomal activity. Thus, proteasomal blockade still does not prevent formation of a defective yeast retromer. By contrast, independent of proteasome function, introduction of the R 107 W mutation into hVps35 prevents the reduction of Vps26 levels (Figure 8A ) while blocking the ability of hVps35 to produce a dominant-negative CPY secretion phenotype ( Figure 8B ).
Expression of hVps35R 107 W in mammalian cells
In preliminary experiments (not shown), both HeLa cells and 293 cells were transiently transfected in which expression of hVps35 or hVps35R 107 W was driven by a cytomegalovirus (CMV) promoter (likely to be stronger than the endogenous promoter for mammalian Vps35). The distribution of hVps35 showed smaller puncta in their cytoplasmic distribution than that seen for hVps35R 107 W. We then examined transfected insulinoma cells to begin to explore the distribution of relevant markers in regulated secretory cells. As in HeLa and 293 cells, in transiently or The CPY filter overlay. Each wild-type strain is transformed with a centromeric plasmid listed first and a 2m plasmid listed second with the protein (or lack of protein) encoded by these plasmids described (at right). B) Sedimentation behavior of hVps35-myc in the presence or absence of overexpressed yVps35. At left, hVps35 is nearly quantitatively associated with the pellet after centrifugation at 100 000 Â g for 1 h (P100). At right, upon overexpression of yVps35, a fraction of hVps35 is displaced into the supernatant (S100). The hVps35 protein was identified by Western blotting with anti-myc. is shown as a negative control. C) Analysis of proalpha factor (paF) processing by the strains shown in panels A and B was carried out as described in the legend to Figure 3 . In this SDS-PAGE system, a number of partially processed alpha factor peptides run with mature alpha factor (aF) at the dye front.
stably transfected INS-1 cells, hVps35-myc showed a more peripheral punctate cytoplasmic distribution than that of hVps35R 107 W-myc ( Figure 9 ). The expression and distribution of wild-type and mutant hVps35-myc in the stably transfected cells was then compared with that of CI-MPR ( Figure 10 ). While hVps35R 107 W-myc immunofluorescence was more enriched in the juxtanuclear region causing greater apparent antigen overlap in this region of the cell, overall MPR immunofluorescence intensity in such cells (Figure 10, arrow Figure 11 , upper row), a population of subplasmalemmal secretory granules was comparable to that in cells not expressing exogenous mammalian Vps35 (this phenotype was found in 91% of the cells). However, in cells expressing hVps35R 107 W-myc, it was apparent that the expression coincided with the loss of most insulin secretory granules (Figure 11 arrows, lower row; this phenotype observed in 78.5% of the cells). These data suggest that hVps35R 107 W has an altered intracellular membrane distribution and interferes with a number of post-Golgi trafficking functions.
Discussion
In this study, we have followed a general approach for developing selective dominant-interfering mutants of mammalian protein trafficking gene products by exploiting evolutionarily conserved protein interaction domains in conjunction with simple yeast genetics. Residue R 98 of Vps35 appeared as an attractive initial candidate to explore mammalian Vps35 because (i) it is a common site of mutation amongst a collection of yeast mutants exhibiting dominant-negative behavior (17) and (ii) the site is highly conserved evolutionarily. Our companion manuscript suggests that yVps35-R 98 W has diminished ability to bind its yVps26 partner and expression of the yVps35-R 98 W mutant results in formation of defective retromer complexes (17) . In the present study, replacement of the first 263 residues of yVps35 with the complementary residues of hVps35, despite imperfect VPS35 function, also conveys enhanced dominant-negative behavior when the conserved Arg residue is mutated to Trp (Figure 1 ), strongly suggesting that the Arg residue -even when embedded within the hVps35 contextual sequenceengages a yeast retromer partner.
In contrast with yVps35, hVps35 exhibits dominantnegative behavior in yeast even before mutagenesis of the PRLYL motif (Figures 2 and 3) . The sequences of hVps35 and yVps35 diverge substantially in the midmolecule and in their carboxyl-terminal regions. Moreover, hVps35 and yVps35 are designed to sort different cargo S-amino acids and chased for the times indicated. At each chase time, cells were lysed and immunoprecipitated with anti-myc, normalized to trichloroacetic acid-precipitable counts. The immunoprecipitates were analyzed by SDS-PAGE and fluorography. B) Wild-type (W303) cells transformed to express the proteins shown or transformed with empty vector (Control) were lysed and the lysates were sedimented at 100 000 Â g for 60 min as described in Materials and Methods. The pellet was resuspended in a volume identical to the supernatant volume, and equal volumes of the pellet and supernatant fractions were analyzed by SDS-PAGE and Western blotting with anti-myc. C) Yeast strain SNY217 carrying plasmid pVps26-HA (9) and either plasmid pGTH12 (hVps35-myc) or pGTH12-R 107 W [hVps35(R 107 W)-myc, also called simply R 107 W] was lysed under native conditions. To confirm the presence of comparable starting amounts of yVps26-HA in each strain, 2% of each lysate was analyzed by SDS-PAGE and immunoblotting with mouse anti-HA antibody (upper gel). From the remaining lysates, immunoprecipitation was performed with rabbit anti-HA antibody using protein A-Sepharose. Fifty percent of the immunoprecipitate (I) and 3.2% of the supernatant (S) were analyzed by SDS-PAGE gel and immunoblotting with mouse anti-c-myc antibody (lower gel) to detect coprecipitated hVps35-myc and hVps35(R 107 W)-myc. Densitometry of the bands, with correction for the percent loaded, back-calculated to the same total myc-tagged protein levels in each strain, and this was also directly confirmed by Western blotting (not shown). P, pellet; S, supernatant.
molecules. Given these considerations, it does not seem surprising that hVps35-myc expression cannot complement a vps35 null (Figure 2A ) and would be more likely to associate with endogenous yeast components to form a dysfunctional retromer complex, specifically through its association with yVps26 ( Figure 6C ). The dominant-negative behavior is effectively reversed merely by raising yVps35 levels ( Figure 4A ), indicating that its specific perturbation occurs within the yeast retromer complex.
In this report, recruitment of hVps35-myc into dysfunctional retromer complexes is strongly suggested by its efficient coimmunoprecipitation with epitope-tagged yVps26 in a strain lacking VPS35 and VPS26. However, when expressed as a dominant negative in (otherwise wild type) yeast, the expression of hVps35 evidently triggers degradation of endogenous Vps26 (and Vps29, see below). In this report, we demonstrate that dominant-negative phenotypes caused by hVps35 are totally blocked by the introduction of the R 107 W mutation -including both CPY secretion and proalpha factor processing ( Figure 5B,C) . Loss of the dominant negative occurs despite that a pool of hVps35R 107 W can still be pelleted at 100 000 Â g for 1 h ( Figure 6B ). We do not know precisely what this persistent sedimentation signifies, but we note that this behavior is virtually identical to the degree of displacement of hVps35-myc from membranes when its specific binding sites are competed away by overexpression of yVps35 ( Figure 4B) ; thus, we interpret the remaining as 'non-specific sedimentation' that may occur even when hVps35 and hVps35R 107 W (both driven by the strong constitutive TDH3 promoter) are expressed in excess of the stoichiometry of their yVps26 retromer partner. Indeed, we have found that both hVps35 and hVps35R 107 W still sediment in strains lacking VPS26 (not shown), and a similar observation has been made for yVps35 in strains lacking VPS29 (18) . Potentially, this additional sedimentation (which requires significant centrifugal force -somewhere between 62 000 and 82 000 Â g; data not shown) might occur through direct membrane association of hVps35 or hVps35R 107 W, perhaps including phospholipid interactions.
We find that hVps35 has a slightly faster turnover in yeast cells than hVps35R 107 W ( Figure 6A ), but more important is the reduced level of yVps26 and yVps29 (Figure 7 ). This reduction is at least partially dependent upon proteasome activity, supporting that hVps35 participates in an unstable complex resulting in the proteasomal destruction of these dynamically associating subunits (Figure 8 ). Importantly, proteasomal dysfunction does not restore normal retromer activity, proving that the hVps35 protein cannot function with yeast retromer partners (Figure 2A ) even when protected from degradation ( Figure 8B ). Taken together, these data signify that retromer subunits that assemble into defective complexes are destroyed, and this may be one mechanism to maintain proper intracellular stoichiometry of functional retromer-binding partners in cells. In support of this conclusion, selective knockdown of either mammalian Vps35 or Vps26 expression has been found to be associated with concomitant knockdown of other members of the Vps35/26/29 subcomplex (8, 14, 19) , and similar instability has previously been reported also in yeast cells (5, 9) .
In mammalian cells, hVps35R 107 W has a more concentrated juxtanuclear distribution than does hVps35 ( Figures  9-11) . Expression of hVps35R 107 W exhibits some overlap of distribution with MPRs in the juxtanuclear region but also causes a decrease in MPR signal strength (e.g. Figure 10 ), which has often been reported as a consequence of perturbed MPR trafficking. Further, the population insulin granules of the regulated secretory pathway are adversely affected by expression of hVps35R 107 W (Figure 11 ). While these studies are consistent with the previous work suggesting a role for retromer in MPR trafficking in mammalian cells (8) , they also imply potential significance of retromer function in the recycling of secretory granule membrane proteins, which is an area that remains largely unexplored (20) (21) (22) .
In conclusion, we have established that the conserved PRLYL motif of hVps35 interacts with yVps26, affecting function of the yeast retromer. Work is ongoing to further characterize the significance of dominant-negative hVps35R 107 W in mammalian cells.
Materials and Methods

Yeast strains and media
Standard yeast media and genetic manipulations were as described previously (23) . Unless otherwise indicated (Table 1) , strains employed in this study are isogenic to W303 or SNY36-9A (24). Strain vps35::LEU2 is the eis1 mutant of L5145/pMI316, displaying enhanced immunoreactive insulin secretion after random mutagenesis and screening (1). Yeast strain SNY183 was prepared from the strain LSY2 by insertional replacement of VPS29 with a VPS29::3xHA-KanR allele using the method of Longtine et al. (25) . Similarly, the SNY175 and SNY176 strains were prepared from strain LSY2 (26) by insertion of a 3xHA tag at the 3 0 end of the VPS17 and VPS26 open reading frames (ORFs) using a polymerase chain reaction (PCR)-mediated approach (27) .
Plasmids and molecular biology
pRSGLC is a TRP1-marked centromeric plasmid [pRS314 (28) ] bearing the TDH3 promoter (29) . For detection of Vps5, cells were transformed with pAH31, a URA3-marked centromeric plasmid encoding 1xHA-yVps5 (30) . In this epitope-tagged construct, the 6th residue of yVps5 was mutated from Asn to Leu. pAH60 is a URA3-marked 2m plasmid (pYEp352) carrying an approximately 3.9-kb EcoRI-SacI DNA fragment containing yVPS35. pAH60-hpX is a series of dominant-negative mutants obtained from PCR mutagenesis on pAH60. pRS314-hpA is a TRP1-marked centromeric plasmid carrying the same approximately 3.9-kb yVPS35 fragment as pAH60. pRS314-hpX are the corresponding dominant-negative vps35 alleles from the pAH60-hpX series subcloned into the pRS314 backbone. The hVps35-myc complementary DNA (cDNA) was kindly provided Dr C. Renfrew Haft (National Institute of Diabetes, Digestive Diseases and Kidney, National Institutes of Health, Bethesda, MD, USA). pT35 encodes hVps35-myc subcloned directly after the TDH3 promoter using BamHI and SalI sites of pRSGLC. pT35RW is the pT35 plasmid encoding hVps35 with the R 107 W single point mutation. pGTH11 encodes the N-terminal HA-tagged hVps35, subcloned directly after the TDH3 promoter, into the BamHI/SalI of pRSGLC; in the coding sequence, the first five residues of hVps35 were replaced by 16 residues containing an initiator methionine and the HA epitope tag. pcDNA3-hVps35 (or pcDNA3-hVps35RW) encodes the C-terminal myctagged hVps35 (or hVps35R 107 W mutant) subcloned directly downstream of the CMV promoter using the BamHI/XhoI sites of vector pcDNA3 (Invitrogen). To make the human-yeast hybrid VPS35 construct known as pNHCY1 an approximately 800 DNA fragment from pGTH11 was amplified by the following primers: GACGTCCATGAGATATT-CTTGAGC (that introduces an AatII site, underlined) and CACCAAGAACTTAG (sequence from TDH3 promoter). The PCR product that includes part of the TDH3 promoter sequence, a BamHI site, ATG, encoded HA-tag sequence (48 nucleotides) and an N-terminal fragment of hVps35 up to residue 263, as well as the AatII site, was subcloned into the pGEM T-vector and linked to an AatII-SalI fragment from yVPS35 (encoding the complete C-terminal fragment of yVps35 beginning at residue 245). The hybrid version was then subcloned to pRSGLC directly downstream of the TDH3 promoter to make plasmid pNHCY1. Plasmid pNHCY1-RW is the mutant derivative of pNHCY1.
Materials
Rabbit polyclonal anti-myc from Santa Cruz Biotech, Inc. was used for immunoblotting at a 1:4000 dilution. Guinea-pig anti-insulin was from Linco Research. Mouse monoclonal antibody (mAb) anti-myc (9E10) was produced in the University of Michigan Hybridoma Core Lab and purchased at Santa Cruz Biotech, Inc. Rabbit polyclonal and mouse monoclonal anti-HA were from Covance Research Co.. Mouse mAb anti-CPY was from Molecular Probes. Rabbit polyclonal anti-alpha factor antibody (RW1) was the kind gift of Dr D. Shields (Albert Einstein College of Medicine, Bronx, NY, USA). Rabbit polyclonal anti MPR was the kind gift of Dr L. Matovcik (Yale University School of Medicine, New Haven, CT, USA). Rabbit polyclonal anti-yVps26 was the kind gift of Dr M. Seaman (University of Cambridge, UK). Secondary antibodies and peroxidase conjugates were from Jackson Immunolaboratories; Zysorbin was from Zymed; protein A and protein G agarose were from Sigma. 
CPY filter-blot assay
To assay secretion of CPY, cell patches were replica plated onto nitrocellulose filters placed on top of the plates. After 24 h, the filter was washed and processed for immunoblotting with mouse mAb anti-CPY and a peroxidase-conjugated secondary antibody (1:10 000 dilution).
Proalpha factor secretion
To examine secretion of proalpha factor, cells were grown to mid-log phase in synthetic complete medium without methionine and cysteine. Cells were harvested and resuspended at 0.8 optical density (OD 600 )/mL in fresh medium with 1 mg/mL bovine serum albumin. Five hundred microCurie of 35 S-amino acid mixture was added to each sample and incubation was continued for 50 min at room temperature with shaking. Media were separated from cells by centrifugation at 19 500 Â g for 5 min. sodium dodecyl sulfate (SDS) was added to the medium to a final concentration of 1%, and samples were boiled for 3 min. Secretion of alpha factor-containing peptides was recovered by immunoprecipitation with the RW1 rabbit polyclonal anti-alpha factor antibody and analyzed by SDS-15%-PAGE and fluorography.
Western blot and membrane sedimentation assay
Steady-state levels of myc or HA-tagged proteins (or endogenous yVps26p) were analyzed in cell lysates prepared from mid-log cultures by vortexing with glass beads as described previously (31) . Unlysed cells were removed by centrifugation at 4500 Â g Â min twice at 48C. Sample loading was normalized to lysate protein as measured by bicinchoninic acid protein assay (Pierce Biotech, Inc.). After SDS-PAGE and electrotransfer to nitrocellulose, blots were probed with anti-myc, anti-HA or anti-Vps26 (1:250 dilution) and a peroxidase-conjugated secondary antibody (1:5000 dilution). Bands were visualized by enhanced chemiluminescence (Amersham).
Membrane sedimentation assays were carried out after harvesting cell lysates using the same lysis method (31) . Unlysed cells were removed by centrifugation at 4500 Â g Â min twice at 48C. The 4500 Â g-min supernatant was then diluted to 1 mg/mL. Three hundred micrograms of cell lysates were centrifuged at 100 000 Â g for 60 min to generate pellet (P100) and supernatant (S100) fractions. The P100 pellet was resuspended in 300-mL lysis buffer (31) to match the volume of the supernatant. All steps, performed at 48C, included presence of a protease inhibitor cocktail (aprotinin 0.25 ug/mL, leupeptin 0.1 mM, pepstatin 10 uM, ethylenediaminetetraacetic acid (EDTA) 5 mM and E64 10 uM). The supernatant and pellet protein distribution was measured by SDS-PAGE and Western blotting.
Metabolic labeling and immunoprecipitation of CPY or hVps35-myc
Cells were grown to exponential phase in synthetic complete medium without methionine and cysteine and then sedimented at 3000 Â g for Table 1 : Yeast strains used in this study
Strains
Genotype Source SNY36-9A MATa leu2-3,112 ura3-52 his3-D200 trp1-901 suc2-9 pho8D::ADE2 (24) LSY2 MATa leu2-3,112 ura3-52 his3-D200 trp1-901 suc2-9 pho8D::ADE2 pep4D::TRP1 (33) SNY175 MATa leu2-3,112 ura3-52 his3-D200 trp1-901 suc2-9 pho8D::ADE2 pep4D::TRP1 VPS17::3xHA This study SNY176 MATa leu2-3,112 ura3-52 his3-D200 trp1-901 suc2-9 pho8D::ADE2 pep4D::TRP1 VPS26::3xHA This study SNY183 MATa leu2-3,112 ura3-52 his3-D200 trp1-901 suc2-9 pho8D::ADE2 pep4D::TRP1 VPS29::3xHA This study PBY35 MATa leu2-3,112 ura3-52 his3-D200 trp1-901 suc2-9 pho8D::ADE2 pep4D::TRP1 vps5D::HIS3 etc.
W303
MATa ade2-1 can1-100 his3-11 leu2-3,112 trp1-1 ura3-52 (34) vps35D
MATa ade2-1 can1-100 his3-11 leu2-3,112 trp1-1 ura3-52 vps35D::HIS3 This study KY146
MATa his3-11 leu2-3,112 ura3-52 can1-100 (35) KY148
MATa his3-11 leu2-3,112 ura3-52 can1-100 pre1-1 pre2-1 (35) BFY106-4D MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 kex2D::HIS3-A (36) SNY217 MATa leu2-3,112 ura3-52 his3-D200 trp1-901 suc2-8 pho8D::ADE2 pep4DÀDH3 vps35D::HIS3 vps26D::NatR This study 5 min and resuspended at 1 OD 600 /mL in the same medium. Cells were labeled with Expre 35 S 35 S at 0.1 mCi per 1 OD 600 cells for 5 min at room temperature and chased in the presence of 10 mM unlabeled methionine and cysteine. At various chase times, aliquots were placed on ice in the presence of 10 mM NaN 3 . In preparation for immunoprecipitation of CPY or hVps35-myc, cells were then sedimented at 3000 Â g for 5 min; in addition, the supernatant containing secreted proteins was collected for further analysis. Lysates were prepared and resuspended in RIPA buffer (10 mM Tris, pH 7.5, 150 nM NaCl, 2 mM EDTA, 1% Nonidet P-40, 1% deoxycholate and 0.1% SDS). All samples received a protease inhibitor cocktail (aprotinin 0.25 mg/mL, leupeptin 0.1 mM, pepstatin 10 mM, EDTA 5 mM and E64 10 mM). Samples were precleared with 20 mL Zysorbin for 30 min (Zymed) and then immunoprecipitated either with 1 mL mouse mAb anti-CPY and protein G-Sepharose beads or with 1 mL rabbit anti-myc antibody and protein A-Sepharose beads.
Mammalian cell culture, transfection and immunofluorescence
INS-1 and INS-832/13 cells were cultured as described previously (32) . A cDNA encoding wild-type hVps35-myc or hVps35-mycR 107 W was subcloned into the pcDNA3 (CMV promoter-driven) expression vector (Invitrogen). Plasmid DNA was transfected into cells using lipofectamine (Gibco/Brl). Transfected INS-1 cells were selected with G418 and then grown on glass coverslips and prepared for immunofluorescence. To allow proinsulin egress from the endoplasmic reticulum, processing and insulin accumulation in secretory granules, cells were treated with cycloheximide (10 mg/mL) for 60 min before fixation. Cells were then fixed with 4% formaldehyde and permeabilized with 0.1% Triton-X-100. After fixation, the cells were incubated for 30 min in 5% newborn bovine serum in PBS containing 0.02% NaN 3 (wash) and then processed for immunodetection. Primary antibodies were diluted in wash, mouse mAb anti-Myc at 1:250 (or rabbit polyclonal antiMyc at 1:500) together with anti-insulin or anti-MPR antibodies (each used at 1:500); antibodies were incubated with the cells for 30 min at room temperature. To assess background staining, anti-myc antibodies were incubated with untransfected cells, whereas guinea-pig IgGs served as a negative control for the insulin antibody. Bound antibodies were detected with secondary antibodies that were Alexa Fluor 488 tagged (Molecular Probes), Alexa Fluor 555 tagged (Molecular Probes) or amino methylcoumarintagged (Jackson ImmunoResearch). Fluorescence was monitored with an Olympus FV500 confocal laser-scanning microscope (Olympus America Inc.) using standard filter settings and sequential scanning to avoid overlap of emission from the fluorophores. The thickness of the optical sections was set to 0.486 mm. Where comparisons between samples were employed, digital images were captured at fixed exposure settings and Photoshop files were transferred with identical settings for image presentation.
